| Literature DB >> 34394838 |
Kamal Fatima Zahra1, Radu Lefter2, Ahmad Ali3, Ech-Chahad Abdellah4, Constantin Trus5, Alin Ciobica6, Daniel Timofte7.
Abstract
Oxygen-free radicals, reactive oxygen species (ROS) or reactive nitrogen species (RNS), are known by their "double-sided" nature in biological systems. The beneficial effects of ROS involve physiological roles as weapons in the arsenal of the immune system (destroying bacteria within phagocytic cells) and role in programmed cell death (apoptosis). On the other hand, the redox imbalance in favor of the prooxidants results in an overproduction of the ROS/RNS leading to oxidative stress. This imbalance can, therefore, be related to oncogenic stimulation. High levels of ROS disrupt cellular processes by nonspecifically attacking proteins, lipids, and DNA. It appears that DNA damage is the key player in cancer initiation and the formation of 8-OH-G, a potential biomarker for carcinogenesis. The harmful effect of ROS is neutralized by an antioxidant protection treatment as they convert ROS into less reactive species. However, contradictory epidemiological results show that supplementation above physiological doses recommended for antioxidants and taken over a long period can lead to harmful effects and even increase the risk of cancer. Thus, we are describing here some of the latest updates on the involvement of oxidative stress in cancer pathology and a double view on the role of the antioxidants in this context and how this could be relevant in the management and pathology of cancer.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34394838 PMCID: PMC8360750 DOI: 10.1155/2021/9965916
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1The distribution of cases for the 10 most common cancers in 2018 for both sexes (source: GLOBOCAN 2018 [83]).
The role of oxidative stress on cancer development.
| Cancer type | Sample collection | Models | Biomarkers | Reference |
|---|---|---|---|---|
| CRC | Human colon tissue, males, mean age 67 yrs, range 60-83, normal tissue ( |
| ↑ROM | Keshavarzian et al. (1992) [ |
| Human colorectal mucosal tissues, normal tissue ( |
| ↑MDA | Otamiri et al. (1989) [ | |
| Urine sample, cancer patients ( |
| ↑8-oxoGua | Roszkowski et al. (2011) [ | |
|
| ||||
| BC | Blood samples (plasma), women with breast cancer ( |
| ↑FORT | Tahari et al. (2013) [ |
| Blood samples, women BBC ( |
| ↑8-OHdG | Eldin et al. (2019) [ | |
| Urine sample, cancer patients ( |
| ↑8-OHdG | Yamamoto et al. (1996) [ | |
| Blood samples (serum), BC patients ( |
| ↑MDA | Hewala et al. (2019) [ | |
|
| ||||
| PC | DU 145 |
| ↑H2O2 | Kumar et al. (2008) [ |
| Blood samples (erythrocytes and plasma), PC patients ( |
| ↓GPx3 | Szewczyk-Golec et al. (2015) [ | |
| Human prostate tissue, PC ( |
| ↓GSH-Px | Zachara et al. (2005) [ | |
|
| ||||
| LC | A/J mice (female |
| ↑8-OHdG | Xu et al. (1992) [ |
Abbreviations: 8-OHdG: 8-hydroxy-20–deoxyguanosine; 8-oxodG: 8-oxo-2′-désoxyguanosine; PLA2: phospholipase A2; MP: myeloperoxidase; CRC: colorectal cancer; BC: breast cancer; ROM: reactive oxygen metabolites; GSH: glutathione (total, reduced); GSSG: glutathione disulfide; LC: lung cancer; MDA: malondialdehyde; TAC: total antioxidant capacity; PC: prostate cancer.